Simulations Plus brings NVIDIA’s BioNeMo Agent Toolkit into agentic drug development workflows

Simulations Plus said it is moving further into “agentic” approaches to drug development, announcing progress that links its model-informed and AI-accelerated discovery efforts with NVIDIA’s BioNeMo Agent Toolkit. The company, which focuses on computation-assisted drug research and development, described the update as part of a broader effort to use AI agents to help orchestrate simulation and analysis across discovery workflows.

The announcement, dated June 23, 2026, comes from Simulations Plus, Inc. (Nasdaq: SLP), in a release distributed via Yahoo Finance. The company said it is advancing agentic drug development with NVIDIA’s BioNeMo Agent Toolkit, positioning the integration as a way to help researchers coordinate tasks that traditionally require multiple tool passes, iterative modeling, and expert review.

While Simulations Plus did not provide detailed performance metrics in the available announcement, the company’s framing suggests the integration is intended to make it easier to run complex simulation loops in a more automated, agent-guided manner. In “agentic” systems, software agents attempt to plan and execute sequences of steps toward a goal, rather than relying on a single static model output. For drug development, that can mean chaining tasks such as data preparation, model runs, and downstream evaluation into a more repeatable process.

For NVIDIA, BioNeMo Agent Toolkit is part of its push to bring model tooling and AI agent capabilities to biological and healthcare use cases. The toolkit approach is designed to help developers build and deploy agent-like workflows, which can be used to connect large models with application logic and domain tools. Simulations Plus’ announcement indicates it is adopting these capabilities to support its own simulation-first approach to accelerating drug development.

Sector context matters because drug R&D is often bottlenecked by the need to iterate rapidly on hypotheses while managing costly experimentation. AI and simulation tools are increasingly positioned as a way to improve throughput and decision quality earlier in the pipeline. Agentic systems are the next evolution in that direction, aiming to reduce the manual coordination work involved in running multiple models and simulations across different stages.

At the same time, the announcement did not spell out which specific workflows are being connected, what datasets are being used, or what measurable outcomes are expected. It also did not disclose any near-term timelines for clinical translation, any partner commitments beyond the integration, or any revenue impact. The lack of disclosed benchmarks means investors and customers will likely look for additional technical detail and validated case studies over time.

What to watch next is whether Simulations Plus shares more concrete results from these agentic workflows, including examples of how tasks are sequenced, how model outputs are checked, and whether the company can demonstrate improvements in turnaround time, experimentation prioritization, or accuracy of simulation-informed decisions. NVIDIA’s ecosystem is also likely to be watched for further healthcare-focused releases that expand what BioNeMo-based agent toolchains can support.